What happened
On October 13, AbbVie released additional results from AFFIRM, a phase 3 trial of subcutaneous risankizumab as initial, or induction, treatment for adults with moderately to severely active Crohn’s disease. The new figures describe what endoscopy showed at weeks 12 and 24, including whether intestinal inflammation met the trial’s definition of remission and whether visible ulcers remained. They do not announce approval of subcutaneous induction: AbbVie says the proposed regimen remains under U.S. and European regulatory review.
Why it matters
Earlier AFFIRM reporting said the trial met its week-12 clinical-remission and endoscopic-response endpoints but did not provide those numerical results in this update. The new figures add a more demanding view of disease control: whether the intestinal lining meets a remission definition or has no visible ulcers, rather than relying only on how patients feel. That information matters to evaluation of a proposed subcutaneous way to begin treatment for adults with active Crohn’s disease. The week-12 comparison supports that evaluation, while the changed treatment paths after week 12 complicate interpretation of the later figures. Neither these results nor the medicine’s existing Crohn’s indication means this induction regimen has been approved.
Evidence
AFFIRM randomized 289 adults two to one between subcutaneous risankizumab and placebo for its initial 12-week induction period. Its co-primary week-12 endpoints were clinical remission, based on symptom and disease-activity scoring, and endoscopic response. AbbVie says earlier reporting found superiority on both, but its October 13 release does not give their numerical results.
The newly detailed endoscopic-remission measure is stricter than endoscopic response. At week 12, 27.7% of the risankizumab group and 10.2% of the placebo group met its definition. Among participants who had visible ulcers at baseline, 26.2% and 10.2%, respectively, had none visible at week 12. These figures are proportions of participants meeting each outcome, not percentages by which their inflammation was reduced.
At week 24, reported overall endoscopic-remission rates were 35.8% for risankizumab and 9.1% for the table’s placebo group; ulcer-free rates were 36.6% and 9.1%. The later figures need a different reading from the initial randomized comparison: after week 12, subsequent blinded or open-label treatment depended on participants’ clinical response. AbbVie reports no new safety signal through week 24, but the release does not give adverse-event counts needed to judge the size of any differences.
What remains unknown
Regulators have not yet decided whether to authorize subcutaneous risankizumab for induction. The release also omits the numerical results for the previously reported co-primary endpoints and detailed adverse-event counts, limiting assessment of the broader benefit and safety picture from this update. Because treatment after week 12 depended on clinical response, the week-24 percentages cannot be read simply as the result of remaining on the original risankizumab-versus-placebo assignments throughout.
Who may be affected
The proposed regimen concerns adults with moderately to severely active Crohn’s disease. AFFIRM included people without prior advanced-therapy failure and people whose earlier advanced therapy had failed; 65% of participants had experienced such a failure.
AXIONOVA connection
AFFIRM illustrates why symptom measures and a direct look at the intestinal lining can add different information about Crohn’s disease. It also requires a separate distinction between an existing Crohn’s indication for risankizumab and approval of this proposed subcutaneous induction regimen. The next decision point is the outcome of regulatory review.
What ALETHA can explain
ALETHA can explain induction versus later maintenance treatment, why symptom-based remission differs from endoscopic findings, and why the response-dependent treatment after week 12 matters when reading the week-24 results. It can also distinguish evidence for a proposed regimen from a regulatory decision authorizing it.
Action posture
Monitor: The new numerical outcomes inform evaluation of a regimen that remains under regulatory review; they do not announce a change to its authorization.